CF PharmTech’s Inhaled siRNA Therapy ICF004 Receives NMPA Clinical Approval for Interstitial Lung Disease

CF PharmTech Inc. (HKG: 2652) announced that China’s National Medical Products Administration (NMPA) has granted clinical trial approval for ICF004 inhalation powder, a novel small interfering RNA (siRNA) drug with potential first-in-class mechanism of action for the treatment of interstitial lung disease (ILD). The therapy will be evaluated in multiple ILD subtypes, including idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), leveraging CF PharmTech’s proprietary inhaled dry powder delivery platform to target diseased lung tissue directly while minimizing systemic exposure.

Regulatory Milestone

Drug Profile & Mechanism of Action

• Molecule: ICF004 – innovative siRNA drug with potential first-in-class mechanism
• Delivery Platform: Inhaled dry powder formulation enabling direct lung delivery
• Targeting Strategy: Maximizes drug concentration in diseased lung areas while minimizing systemic circulation
• Preclinical Evidence:
• Differential distribution: High lung tissue exposure with low systemic blood exposure
• Anti-fibrotic activity: Demonstrated efficacy in preclinical fibrosis models
• Safety profile: Favorable tolerability in preclinical studies
• Therapeutic Rationale: Addresses unmet need in progressive fibrotic lung diseases with limited treatment options

Disease Context & Market Opportunity

Interstitial lung disease (ILD) represents a significant unmet medical need in China and globally:

• Patient Population: Estimated 300,000–500,000 ILD patients in China, with IPF accounting for approximately 30% of cases
• Treatment Gap: Current therapies (pirfenidone, nintedanib) slow but do not halt disease progression and carry significant side effects
• Mortality Impact: IPF has a median survival of 3–5 years from diagnosis, highlighting urgent need for more effective therapies
• Market Potential: Global anti-fibrotic market projected to reach $8–12 billion annually by 2030

The inhaled delivery approach offers several strategic advantages:

• Targeted Therapy: Direct delivery to affected lung tissue enhances efficacy while reducing systemic toxicity
• Patient Compliance: Dry powder inhalation provides convenient outpatient administration
• Differentiation: First siRNA-based therapy specifically developed for inhaled delivery in fibrotic lung disease

“This clinical approval marks a significant milestone in our mission to develop transformative RNA therapeutics for serious respiratory diseases,” said Dr. Wang Jian, Chief Executive Officer of CF PharmTech. “ICF004’s targeted delivery to diseased lung tissue, combined with its novel siRNA mechanism, has the potential to address the fundamental drivers of fibrosis while offering improved safety compared to current systemic therapies.”

Strategic Implications & Competitive Landscape

CF PharmTech’s entry into the ILD market positions the company at the forefront of RNA therapeutics innovation:

• Platform Validation: Success would validate CF PharmTech’s inhaled siRNA delivery platform for other respiratory indications
• First-Mover Advantage: Potential to become the first inhaled siRNA therapy approved for fibrotic lung disease globally
• Competitive Differentiation: Distinct mechanism of action compared to existing anti-fibrotic small molecules
• Global Expansion: Positive clinical data could support international regulatory filings in major markets

Industry analysts view ICF004 as a high-potential asset with peak annual sales potential of $500 million–$1 billion if clinical development proves successful, given the substantial unmet need and premium pricing potential for breakthrough therapies in progressive fibrotic diseases.

Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical development, regulatory approvals, and market opportunities for ICF004. Actual results may differ due to clinical trial outcomes, regulatory decisions, and competitive dynamics.-Fineline Info & Tech